SCHEMBL23948573

SCHEMBL23948573

Cn1c(=O)n(C2CC3COCC3C2)c2nc(Cl)ncc21

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 19/20 0.42
JAK2 O60674 1/20 0.38
JAK3 P52333 1/20 0.38
TTK P33981 2/20 0.38
KCNH2 Q12809 1/20 0.38
PIK3CD O00329 1/20 0.38
CSF1R P07333 1/20 0.38
PIK3R1 P27986 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
MTOR P42345 1/20 0.38
PIK3CG P48736 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28712893 1.00 PRKDC (0.42) PRKDCJAK2JAK3TTKKCNH2
SCHEMBL21593700 0.90 PRKDC (0.43) PRKDCJAK2JAK3TTKKCNH2
SCHEMBL23948559 0.88 PRKDC (0.47) PRKDCTTKKCNH2CSF1RPIK3CA
SCHEMBL23948235 0.88 PRKDC (0.47) PRKDCTTKKCNH2CSF1RPIK3CA
SCHEMBL23620537 0.86 PRKDC (0.49) PRKDCTTKKCNH2CSF1RPIK3CA
SCHEMBL29502052 0.86 PRKDC (0.49) PRKDCTTKKCNH2CSF1RPIK3CA
SCHEMBL24963661 0.85 PRKDC (0.40) PRKDCJAK2JAK3TTKKCNH2
SCHEMBL20299437 0.83 PRKDC (0.53) PRKDCJAK2JAK3TTKKCNH2
SCHEMBL21591874 0.83 PRKDC (0.53) PRKDCJAK2JAK3TTKKCNH2
SCHEMBL29501888 0.83 PRKDC (0.53) PRKDCJAK2JAK3TTKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114315834-B Imidazolone derivatives and their use in medicine 成都百裕制药股份有限公司 2024-01-05 CN disclosed
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2023-06-01 US disclosed
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2023-06-01 US disclosed
EP-4137491-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) 2023-02-22 EP disclosed
EP-4137491-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) 2023-02-22 EP disclosed
CN-114315834-A Imidazolidinone derivatives and their use in medicaments 成都百裕制药股份有限公司 2022-04-12 CN disclosed
WO-2021209055-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE 成都百裕制药股份有限公司 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF SYMPK, PAICS, CYP2C9 PRKDC 316/4885JAK2 537/4885JAK3 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.